South Korea, US Discuss Warship Building Cooperation 
Mercedes-Benz Eyes €800 Million Labor Cost Cuts in Germany 
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
Japanese Bank Stocks Surge as Bond Yields Fuel Rate Hike Bets 
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up 
Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
US Stock Futures Fall as Treasury Yields Surge Ahead of Trump-Xi Summit 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
H&M Q3 Profit Beats Estimates as Margins Improve 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
Add as a preferred source on Google
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
